RXO's valuation has become more attractive following the fallout from the Lipe V. Lupus Superior verdict, in which a jury awarded approximat
RXO's valuation has become more attractive following the fallout from the Lipe V. Lupus Superior verdict, in which a jury awarded approximately $604M against Lupus Superior, its driver, and CHRW @ Benchmark
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.